Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
Sign Up to like & getrecommendations! Published in 2022 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-022-00607-x
Abstract: Imipenem/cilastatin/relebactam (IMI/REL), a combination β-lactam antibiotic (imipenem) with a novel β-lactamase inhibitor (relebactam), is an efficacious and well-tolerated option for the treatment of hospitalized patients with gram-negative (GN) bacterial infections caused by carbapenem-non-susceptible (CNS) pathogens.… read more here.
Keywords: imipenem; imi rel; cost; cms imi ... See more keywords
Imipenem–Relebactam and Meropenem–Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations
Sign Up to like & getrecommendations! Published in 2017 at "Drugs"
DOI: 10.1007/s40265-017-0851-9
Abstract: Relebactam (formerly known as MK-7655) is a non-β-lactam, bicyclic diazabicyclooctane, β-lactamase inhibitor that is structurally related to avibactam, differing by the addition of a piperidine ring to the 2-position carbonyl group. Vaborbactam (formerly known as… read more here.
Keywords: imipenem; vaborbactam; imipenem relebactam; meropenem vaborbactam ... See more keywords
Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem.
Sign Up to like & getrecommendations! Published in 2020 at "Clinical therapeutics"
DOI: 10.1016/j.clinthera.2020.06.010
Abstract: PURPOSE This study explores factors that affect behavior in critically ill patients receiving continuous renal replacement therapy (CRRT) with imipenem and provides dosing regimens for these patients. METHODS A prospective, open-label study was conducted in… read more here.
Keywords: imipenem; pharmacodynamic analysis; analysis; model ... See more keywords
Aztreonam in combination with imipenem-relebactam against clinical and isogenic strains of serine and metallo-β-lactamase-producing enterobacterales.
Sign Up to like & getrecommendations! Published in 2022 at "Diagnostic microbiology and infectious disease"
DOI: 10.1016/j.diagmicrobio.2022.115674
Abstract: OBJECTIVE The objective of this study was to evaluate the in vitro activity of aztreonam plus imipenem-relebactam against clinical and isogenic strains of Escherichia coli and Klebsiella pneumoniae co-harboring NDM and >1 serine β-lactamase. METHODS… read more here.
Keywords: relebactam clinical; combination; lactamase; imipenem relebactam ... See more keywords
Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2020.1790525
Abstract: ABSTRACT Introduction The addition of the β-lactamase inhibitor relebactam to imipenem restores the antibacterial activity against the majority of multidrug resistant Gram-negative bacteria. Complicated urinary tract infections (UTIs) are predominantly caused by Gram-negative uropathogens. The… read more here.
Keywords: imipenem; relebactam; urinary tract; complicated urinary ... See more keywords
In vitro evaluation of double‐carbapenem combinations against OXA‐48‐producing Klebsiella pneumoniae isolates using time‐kill studies
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Medical Microbiology"
DOI: 10.1099/jmm.0.000725
Abstract: Purpose. The aim of this study was to evaluate the in vitro activity of double‐carbapenem combinations against OXA‐48‐producing Klebsiella pneumoniae clinical isolates. Methodology. Double combinations of ertapenem, meropenem and imipenem were evaluated for synergy and… read more here.
Keywords: imipenem; methodology; double carbapenem; carbapenem combinations ... See more keywords
In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of medical microbiology"
DOI: 10.1099/jmm.0.001142
Abstract: Introduction. Infections attributable to carbapenem-resistant Gram-negative bacilli are increasing globally. New antimicrobial agents are urgently needed to treat patients with these infections.Aim. To describe susceptibility to the novel carbapenem-β-lactamase inhibitor combination imipenem-relebactam and comparators of… read more here.
Keywords: imipenem; relebactam; urinary tract; imipenem relebactam ... See more keywords
In Vitro Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli
Sign Up to like & getrecommendations! Published in 2018 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.00533-18
Abstract: Understanding which antimicrobial agents are likely to be active against Gram-negative bacilli can guide selection of antimicrobials for empirical therapy as mechanistic rapid diagnostics are adopted. In this study, we determined the MICs of a… read more here.
Keywords: imipenem; relebactam; negative bacilli; gram negative ... See more keywords
Effectiveness of imipenem-relebactam for multidrug-resistant Pseudomonas aeruginosa in pneumonia and bloodstream infections in the United States (MIRAGE)
Sign Up to like & getrecommendations! Published in 2025 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01325-25
Abstract: ABSTRACT Imipenem-relebactam demonstrates in vitro activity against multidrug-resistant (MDR) Pseudomonas aeruginosa, but real-world effectiveness data are limited. MIRAGE was a multicenter, retrospective, observational study of imipenem-relebactam for MDR P. aeruginosa pneumonia and bacteremia. Patients were… read more here.
Keywords: pseudomonas aeruginosa; imipenem relebactam; multidrug resistant; imipenem ... See more keywords
Imipenem/Cilastatin/Relebactam Alone and in Combination against Pseudomonas aeruginosa in the In Vitro Pharmacodynamic Model
Sign Up to like & getrecommendations! Published in 2020 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.01764-20
Abstract: Combination therapy may enhance imipenem/cilastatin/relebactam’s (I/R) activity against Pseudomonas aeruginosa and suppress resistance development. Human-simulated unbound plasma concentrations of I/R at 1.25 g every 6 h (h), colistin at 360 mg daily, and amikacin at 25 mg/kg… read more here.
Keywords: combination; imipenem cilastatin; imipenem; cilastatin relebactam ... See more keywords
Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants
Sign Up to like & getrecommendations! Published in 2019 at "Antimicrobial Agents and Chemotherapy"
DOI: 10.1128/aac.02165-19
Abstract: Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed… read more here.
Keywords: clinical isolates; aeruginosa clinical; imipenem relebactam; imipenem ... See more keywords